GSK PLC

GSK’s 2026 Q2 report shows 14% specialty‑medicine growth, 8% vaccine boost, and a £1.9bn cost‑saving plan, positioning it for strong profit and future R&D success.

GSK’s acquisition of Nuvalent and FDA‑approved Jideytro boosts its precision‑oncology pipeline, targeting the high‑value ROS1‑NSCLC niche with a cost‑efficient, platform‑based strategy.

GSK’s $10.6B Nuvalent acquisition fuels its solid‑tumour oncology push, adding lung‑cancer ADC assets, new market entry, and a strong moat against patent erosion.

GSK’s Jemperli shows breakthrough 12‑month remission in dMMR/MSI‑H rectal cancer, promising surgery‑free therapy and reshaping oncology strategy.

GSK’s $1.3 billion Nuvalent buy‑out propels its platform‑first oncology strategy, boosting targeted therapies, cell‑therapy expertise and future revenue while managing patent‑expiry risks.

European pharma and biotech firms face volatile markets; learn how GSK and others use value‑based pricing, early approvals, and M&A to beat patent cliffs and drive growth.

GSK’s bepirovirsen hits a 20 % functional cure in phase‑III HBV trials, offering a premium, one‑time treatment that could reshape global pricing, reimbursement, and investor sentiment.

GSK’s May share‑repurchase boosts EPS modestly, yet its stock remains flat amid competitive pricing pressures, LOER risks, and a focus on value‑based reimbursement and pipeline strength to protect profitability and shareholder value.

GSK plc completes Pfizer exit from ViiV Healthcare, boosts its stake and executes a £2,000‑pence share buy‑back—optimising capital, governance, and shareholder value.

GSK’s first‑quarter approvals in China—Exdensur for severe asthma and bepirovirsen for hepatitis B—promise cost‑effective, value‑based therapies that boost clinical outcomes while easing payer budgets.